{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-24-000048","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2024-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.330485+00:00","generated_at":"2026-05-30T17:36:45.666810+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Myriad Genetics expects Q3 2024 revenue of $210-212M, reaffirms FY2024 guidance","bullets":["Preliminary Q3 2024 revenue expected between $210M and $212M.","Full-year 2024 revenue guidance reaffirmed at $835M-$845M.","Divestiture of EndoPredict business in Europe closed on August 1, 2024.","Results are preliminary and unaudited; subject to finalization."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-24-000048","json":"https://secwatch.observer/filing/0000899923-24-000048.json","markdown":"https://secwatch.observer/filing/0000899923-24-000048.md","text":"https://secwatch.observer/filing/0000899923-24-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000048/0000899923-24-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000048/mygn-20241009.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T17:36:45.666810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}